

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 October 2006 (19.10.2006)

PCT

(10) International Publication Number
WO 2006/108864 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/EP2006/061565

(22) International Filing Date: 12 April 2006 (12.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/671,669 15 April 2005 (15.04.2005) US

(71) Applicants (for all designated States except US): **Dominion Pharmakine S.L.** [ES/ES]; Edificio 801A, 1ª planta, Parque Tecnológico de Bizkaia., E-48160 Derio (bizkaia) (ES). **Universidad del País Vasco** [ES/ES]; Universidad del País Vasco., Bº Sarriena s/n, E-48940 Leioa (bizkaia) (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COSSÍO, Fernando Pedro** [ES/ES]; Universidad del País Vasco, Bº Sarriena s/n., E-48940 Leioa (bizkaia) (ES). **ALDABA ARÉVALO, Eneko** [ES/ES]; Universidad del País Vasco, Bº Sarriena s/n., E-48940 Leioa (bizkaia) (ES). **VARA SALAZAR, Yosu Ion** [ES/ES]; Universidad del País Vasco, Bº Sarriena s/n., E-48940 Leioa (bizkaia) (ES). **ZUBIA OLASCOAGA, Aizpea** [ES/ES]; Universidad del País Vasco, Bº Sarriena s/n., E-48940 Leioa (bizkaia) (ES). **VIVANCO AMATO, Silvia** [ES/ES]; Universidad del País Vasco, Bº Sarriena s/n., E-48940 Leioa (bizkaia) (ES). **MENDOZA ARTECHE, Miren Lorea** [ES/ES]; Dominion Pharmakine S.L., Edificio 801a, 1ª Planta, Parque Tecnológico De Bizkaia, E-48160 Derio (bizkaia) (ES). **SALADO POGONZA, Clarisa** [ES/ES]; Dominion Pharmakine S.L., Edificio 801a, 1ª Planta, Parque Tecnológico

De Bizkaia, E-48160 Derio (bizkaia) (ES). **GALLOT ESCOBAL, Natalia** [ES/ES]; Dominion Pharmakine S.L., Edificio 801a, 1ª Planta, Parque Tecnológico De Bizkaia, E-48160 Derio (bizkaia) (ES). **VIDAL VANACLOCHA, Fernando** [ES/ES]; Dominion Pharmakine S.L., Edificio 801a, 1ª Planta, Parque Tecnológico De Bizkaia, E-48160 Derio (bizkaia) (ES).

(74) Agent: **PONS ARIÑO, Angel**; Pons Patentes y Marcas, Glorieta De Ruben Darío 4., E-28010 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF

(57) Abstract: This invention is related to new nitrogenated trans-stilbene analog compounds, more specifically, imine, pyrrol and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.



WO 2006/108864 A2

NEW NITROGENATED TRANS-STILBENE ANALOGS, METHOD FOR THE OBTENTION AND MEDICAL APPLICATIONS THEREOF

5 This invention is related to new nitrogenated trans-stilbene analog
compounds, more specifically, imine, pyrrol and indole derivatives, with
procedures for the preparation and use thereof as pharmaceutical
compositions for the treatment and/or chemoprevention of those
10 mammalian diseases such as cancer, fibrosclerosis and acute/chronic
inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury
in stroke and heart attack, neurodegeneration, and during organ
transplantation, whose pathogenic and pathophysiological mechanisms
depend on or are significantly contributed by undesirable oxidative stress,
angiogenic and proliferative responses.

15

BACKGROUND OF THE INVENTION

It is known that the chemical synthesis of aromatic imines (or Schiff bases)
can generally be achieved by means of the condensation between primary
20 amines and carbonylic compounds (cf. Patai, *The Chemistry of Carbon-
Nitrogen Double Bond*; Wiley: New York, 1970, pp. 64).

Likewise, polysubstituted pyrrol rings can be chemically synthesized in
different ways by employing linear or convergent synthesis methodologies
25 (cf. Sundberg, *Comprehensive Heterocyclic Chemistry*; Katrizki, A. and
Rees, C. W. Eds.; Pergamon: Oxford, 1984; vol. 4, pp. 313). One
sufficiently general way consists of the aromatization of substituted
pyrrolidines (cf. Fejes et al. *Tetrahedron* 2000, vol. 56, pp. 8545; Gupta et
al. *Synth. Commun.* 1998, vol. 28, pp. 3151). The final heterocycles can be
30 prepared, in turn, by means of the 1,3-dipolar reaction between azomethine
ylides and electronically deficient alkenes (cf. Ayerbe et al. *J. Org. Chem.*
1998, vol. 63, pp. 1795; Vivanco et al. *J. Am. Chem. Soc.* 2000, vol. 122,
pp. 6078).

Methods also abound for the synthesis of indoles (cf. Horton et al. *Chem. Rev.* 2003, vol. 103, pp. 893), one of which is a convergent procedure described in literature consisting of the thermal cyclation between primary arylamines and haloacetophenone derivatives (cf. Nyerges et al. *Tetrahedron Lett.* 2005, vol. 46, pp. 377). However, the yields obtained by this method are not usually very high, due mainly to the relatively high temperatures and the lengthy reaction times necessary for completing the cyclation reaction and the ease with which the reagents may degrade under these conditions.

10

Oxidative stress facilitates carcinogenesis (Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. *Front Biosci.* 2006;11:300-12) and the prometastatic and proangiogenic mechanisms of cancer (Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H, Toyokuni S. Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis. *Oncogene.* 2004;23:3980-9) and many other diseases (Casetta I, Govoni V, Granieri E. stress, antioxidants and neurodegenerative diseases. *Curr Pharm Des.* 2005;11(16):2033-52; Sukkar SG, Rossi E. Oxidative stress and nutritional prevention in autoimmune rheumatic diseases. *Autoimmun Rev.* 2004;3:199-206; Naito Y, Takano H, Yoshikawa T. Oxidative stress-related molecules as a therapeutic target for inflammatory and allergic diseases. *Curr Drug Targets Inflamm Allergy.* 2005;4:511-5.). Thus, numerous cancer research studies have focused their attention on the effects of some natural antioxidant compounds (resveratrol, quercetin, vitamin C, etc.) as chemopreventive agents of carcinogenesis and metastasis. In some cases, it has been proven that said action is caused not solely by means of the antioxidant effect of said agents, but also by way of their action of blocking cyclooxygenases (COX) and tyrosine kinases.

30

On the other hand, the mechanism of action of most of the proinflammatory and prometastatic factors is regulated by oxygen-reactive metabolites. In

5 this regard, it has been proven that treating animals with catalase prior to their being intrasplenically inoculated with B16 melanoma cells reduces the onset of hepatic metastasis, which indicates that hydrogen peroxide (H₂O₂), released in response to hepatic colonization by tumor cells, has prometastatic effects (cf. Anasagasti et al., "Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice". *Hepatology*. 1997, vol. 25 pp.840-6).

10

Trans-stilbene compounds, particularly trans-resveratrol, are widespread throughout nature, mainly in the form of phytoalexins and are attracting growing interest due to a wide range of biological activities useful in oncology, such as the inhibition of carcinogenesis (cf. Jang et al., *Science* 1997, vol. 275, pp. 218; Gosslan et al., *Brit. J. Cancer*. 2005, vol. 92, pp. 513) and apoptosis induction (cf. Lee et al., *Life Sci*. 2004, vol. 75, pp. 2829). This biological activity has been attributed to the antioxidant properties (cf. Stivala et al., *J. Biol. Chem*. 2001, vol. 276, pp. 22586) and anti-inflammatory properties (cf. Kimura et al., *Biochim. Biophys. Acta* 1985, vol. 834, pp. 275) of these compounds, as a result of which they can serve as chemopreventive and chemotherapeutic agents (cf. De Lédinghen et al., *Int. J. Oncol*. 2001, vol. 19, pp. 83; Scheneider et al., *Nutr. Cancer* 2001, vol. 39, pp.102; Mahyer-Roemer et al., *Int. J. Cancer* 2001, vol. 94, pp. 615). It is known that trans-stilbenes are able to isomerize the cis- form which is either inactive or less active. For example, trans-resveratrol can isomerize under the effect of sunlight to convert partially into the cis isomer (cf. F. Olalla, *Curr. Med. Chem*. 2006, vol 13, pp. 87-98; I. Kolouchová-Hanzlíková et al. *Food Chem*. 2004, vol. 87, pp. 151-158).

30 DESCRIPTION OF THE INVENTION

Brief description of the invention

35 The invention described herein is related to nitrogenated polyhydroxylated and/or polyalcoxylated trans-stilbene analog compounds, which include imine derivatives, pyrrol derivatives or indole derivatives, useful as inhibitors

of inflammatory agents, oxidative stress, angiogenesis-related effects, metastasis and cancer progression. This invention is also related to therapeutic compositions which include said compounds and the use thereof for the treatment and prophylaxis of cancerous and inflammatory diseases, such as, but not limited to, cancer metastasis. This invention is also related to the methods for obtaining said compounds.

Description of the figures

Fig. 1.- Shows the optimized structures, calculated using the MP3 method (cf. Stewart, J. *Comput. Chem.* 1989, vol. 10 pp. 209), of (A) trans-stilbene; (B) diphenylamine; (C) 2,4-diphenyl-1H-pyrol; y (D) 2 phenyl-1H-indole.

Fig. 2.- Shows the inhibitory effect of the compounds JE1:2, JE2:1 and JE2:2 on the adhesion of the murine B16 melanoma (MB16) cells treated or not with non-toxic concentrations of H₂O₂ to immobilized recombinant VCAM-1 substrates. The differences in adhesion with regard to the untreated MB16 cells (*) and the MB16 cells treated with H₂O₂ (**) are statistically significant (P<0.01) according to Student's t-test.

Fig. 3.- Shows the inhibitory effect of the compounds JE1:2, JE2:1 and JE2:2 on the in vitro proliferation of MB16 cells treated or not with recombinant IL-18. The differences in proliferation with regard to the untreated MB16 cells (*) and the MB16 cells treated with IL-18 (**) are statistically significant (P<0.01) according to Student's t-test.

Fig. 4.- Shows the inhibitory effect of the compound JE2:2 on the production of H₂O₂ from MB16, treated or not with recombinant IL-18 in vitro.

Fig. 5.- Shows the inhibitory effect of the compounds JE1:2, JE2:1 and JE2:2 on the production of H₂O₂ from primary cultured mouse hepatic sinusoidal endothelium (HSE) cells.

Fig. 6.- Shows the inhibitory effect of the compound JE2:2 on the adhesion of MB16 cells to the primary cultured mouse HSE cells treated or not with

MB16 conditioned media (MC-MB16). The differences in adhesion with regard to the untreated HSE cells (*) and the HSE cells treated with MC-MB16 (**) are statistically significant ($P < 0.01$) according to Student's t-test.

5 Fig. 7.- Shows the effects of the compounds JE2:2-01 and JE2:1-02 on the adhesion of the MB16 cells treated or not with H₂O₂ to immobilized VCAM-1 substrates. The differences in adhesion with regard to the untreated MB16 cells (*) and the MB16 cells treated with H₂O₂ (**) are statistically significant ($P < 0.01$) according to Student's t-test.

10

Fig. 8.- Shows the inhibitory effect of JE2:2-01 and JE2:1-02 (A) on the adhesion of MB16 cells and (B) on the production of TNF-alpha from HSE cells treated or not with MC-MB16. The differences in the adhesion or in the concentration of TNF-alpha with regard to the untreated HSE cells (*) and the HSE cells treated with MC-MB16 (**) are statistically significant ($P < 0.01$) according to Student's t-test.

15

Fig. 9.- Shows the inhibitory effect of the compounds YEF02, YEF03, YEF07, YEF05B, YEF07B and YEF05H on the adhesion of MB16 cells treated or not with H₂O₂ to immobilized VCAM-1 substrate. The differences in adhesion between untreated MB16 cells (*) and H₂O₂-treated MB16 cells (**) are statistically significant ($P < 0.01$) according to Student's t-test.

20

Fig.10.- Shows the inhibitory effect of the compounds YEF02, YEF03, YEF07, YEF05B, YEF07B and YEF05H on the adhesion of MB16 cells to HSE treated or not with MC-MB16. The differences in adhesion with regard to untreated (*) and the MC-MB16-treated (**) HSE cells are statistically significant ($P < 0.01$) according to Student's t-test.

25

Fig. 11.- Shows the inhibitory effect of the compounds JE22, YEF07 and YEF05B on the production of PGE₂ (as evidence of cyclooxygenase-2 activity) by HSE cells in response to VEGF. The differences in the PGE₂ production between untreated (*) and VEGF-treated (**) HSE cells are statistically significant ($P < 0.01$) according to Student's t-test.

30

35

Fig. 12A, Fig. 12B y Fig. 12C.-Effect of the compound JE2:2 on the


development of hepatic metastasis following the intrasplenic injection of basal medium-cultured MB16 cells in C57BL/6J mice.

Detailed description of the invention

5

According to the first aspect of the invention described herein, a nitrogenated compound of polyhydroxylated and/or polyaloxylated trans-stilbene is provided with the following general formula (I):



10



or any of the salts thereof, where:

15

(X) is selected from between the following groups, imine or pyrrole:



20

In the case in which the group (X) is a pyrrole group, it may be bonded to the phenyl group (A) by one or two of its pyrrole ring carbons. When it is bonded by two of its carbons, then (D) and (Y) form part of the ortho-disubstituted phenyl group (A);

25

(D) is the phenyl ring (A) (aromatic ring (A) of the general structure (I);

(U) may be selected from among a hydrogen atom, a linear or branched alkyl group (C₁-C₁₀) or the phenyl group (B) (aromatic ring (B) of general formula (I);

5

(Y) may be selected from among a hydrogen atom or a group selected from among nitro (NO₂), amino (NR₂), linear or branched alkoxy carbonyl (-C(=O)OR), amide (NRC(=O)R') or an organic or inorganic quaternary ammonium salt (NR₄⁺), such as, for example but not limited to, quaternary ammonium chloride or tartrate;

10

(Y) does not exist when the carbon to which it is bonded forms part of the phenyl A ortho-disubstituted group

15

(W) may be selected from among a hydrogen atom or a group selected among carboxyl (-C(=O)OR) or aminocarbonyl [(C(=O)NRR') mono or disubstituted for alkyl, aryl or heteroaryl groups] or (W) is the phenyl group (B) (aromatic ring (B) of general formula (I)

20

(Z) may be selected from among a hydrogen atom or a group selected from among a linear or branched alkyl (C₁-C₁₀), benzyl (-C₆H₅), carboxyl and analogs (-C(=O)OR), arylalkyl, heteroarylmethyl, O-alkyl(aryl)carbamoyl or N-alkyl(aryl)semicarbazide.

25

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ may be the same or different and are selected from among a hydrogen atom or a group selected between alkoxy (-OR) and hydroxyl (-OH), where at least three of these substituents are either alkoxy and/or hydroxyl.

30

R⁵ is absent when the pyrrole ring is bonded to ring (A) by two of its carbon atoms.

35

In the invention described herein, the term "alkyl" C₁-C₁₀, is a saturated linear or branched-chain hydrocarbon which includes from 1 to 10 carbon atoms. The alkyl groups preferred in this invention are, but are not limited to, those which have 1 to 5 carbon atoms, for example, the methyl, ethyl,

propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and isopentyl groups.

5 The term "alkoxy" means an (-OR) radical, where R is a linear or branched alkyl chain of 1 to 10 carbon atoms. The alkoxy groups preferred in this invention are, but are not limited to, those having 1 to 5 carbon atoms, such as, for example, methoxyl, etoxyl, propoxyl, isopropoxyl, butoxyl, pentoxyl, sec-butoxyl or tert-butoxyl.

10 The term "amine" means a radical (-NR₂), where the two R groups may be the same or different and represent a hydrogen atom or a linear or branched alkyl chain of 1 to 10 carbon atoms. The amino groups preferred in this invention are, but are not limited to, those in which both R are hydrogen or one thereof is an alkyl chain of 1 to 5 carbon atoms, more preferably of 1 or 2 carbon atoms.

20 The term "arylalkyl" means a linear or branched chain of 1 to 5 carbon atoms which is substituted by an aryl radical, where the term "aryl", in this invention, means a substituted or non-substituted phenyl radical. The group is preferably, but not limited to, an arylmethyl.


25 The term "heteroarylalkyl" means a linear or branched chain of 1 to 5 carbon atoms which is substituted by an aromatic radical of 5 or 6 bonds with one, two or three heteroatoms, understood as being the elements nitrogen, oxygen and sulfur.

30 The term "carboxyl" (-C(=O)OR) encompasses a carboxylic acid (R=H) and an ester in which R may be a linear or branched alkyl group (linear or branched "alkoxycarbonyl"), or a cyclic alkyl group.

35 The term "amide" means a radical with the form (-NCR(=O)R') where the R and R' groups may be the same or different and represent an atom of hydrogen or a linear or branched alkyl chain of 1 to 10 carbon atoms. The amide groups preferred in this invention are, but are not limited to, those in which both R's are hydrogen and one thereof is an alkyl chain of 1 to 5 carbon atoms, more preferably of 1 or 2 carbon atoms.

The term "aminocarbonyl" means a radical with the form (-C(=O)NRR') where the R and R' groups may be the same or different and represent a hydrogen atom or a linear or branched alkyl chain of 1 to 10 carbon atoms or an aryl or a heteroaryl group.

In one preferred embodiment of the invention described herein, a formula (II) compound is provided, which is obtained on substituting (X) in the general formula (I) with an imine group:




or any of the salts thereof, where:
R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ are of the same meaning as previously stated hereinabove for the general formula (I).

In a more preferred embodiment of the invention described herein, the general formula (II) compound is, but is not limited to, 5-((E)-(4-Hydroxyphenylimine)methyl)benzene-1,3-diol.

In another preferred embodiment of the invention described herein, a compound with the formula (III) is provided, which is obtained on substituting (X) in the general formula (I) with a pyrrole group:

10



or any of the salts thereof, where

5 R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and group (Z) are of the same meaning as previously stated hereinabove for the general formula (I);

(Y) may be selected from among a hydrogen atom or a group selected from among nitro (NO_2), amine (NR_2), linear or branched alkoxy carbonyl ($-\text{C}(=\text{O})\text{OR}$), amide ($-\text{C}(=\text{O})\text{N}-\text{RR}'$) or aminocarbonyl ($\text{NRC}(=\text{O})\text{R}'$) or an
 10 organic or inorganic quaternary ammonium salt (NR_4^+), such as, for example, but not limited to, quaternary ammonium chloride or tartrate;


(W) may be selected from among a hydrogen atom or a group selected
 15 between carboxyl ($-\text{C}(=\text{O})\text{OR}$) or aminocarboxyl ($-\text{C}(=\text{O})\text{NRR}'$).

One preferred embodiment of the invention described herein entails a general formula (III) compound where (Z) is a hydrogen atom; (W) is a group selected between $-\text{COOCH}_3$ or $-\text{COOH}$; (Y) is a hydrogen atom or a
 20 group selected between $-\text{NH}_2$ or $-\text{NO}_2$; R^1 , R^5 , R^6 are R^{10} a hydrogen atom; and R^2 , R^3 , R^4 , R^7 , R^8 and R^9 are the same or different and represent a hydrogen atom or a group selected between $-\text{OCH}_3$ or $-\text{OH}$.

A more preferred embodiment of the invention described herein entails a
 25 general formula (III) compound where (Z) and (Y) are hydrogen atoms.

An even more preferred embodiment of the invention described herein entails a general formula (III) compound selected, but without limitation, from among the following group: 3-(4-methoxyphenyl)-5-(dimethoxyphenyl)-1H-pyrol-2-carboxylic acid, 3,5-bis(3,5-Dihydroxyphenyl)-1H-pyrol-2-methyl carboxylate, 3,5-bis(3,5-Dimethoxyphenyl)-1H-pyrol-2-methyl carboxylate, 5-(3,5-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-1H-pyrol-2-methyl carboxylate, 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrol-2-methyl carboxylate, 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrol-2-methyl carboxylate, 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrol-2-carboxylate, 4-amino-3,5-bis(3,5-dimethoxyphenyl)-1H-pyrol-2-methyl carboxylate, 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrol-2-methyl carboxylate, 3,5-bis(3,5-dimethoxyphenyl)-4-nitro-1H-pyrol-2-methyl carboxylate, 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrol-2-carboxylic acid, and 3-(3,5-Dihydroxyphenyl)-5-(4-hydroxyphenyl)-1H-pyrol-2-methyl carboxylate.

One further embodiment of the invention described herein provides a formula (VI) compound which is obtained on substituting (X) in the general formula (I) with a pyrrole group bonded to the aromatic ring (A) by two of its carbon atoms:



25

(IV)

or any of the salts thereof, where R¹, R², R³, R⁴, R⁶, R⁷, R⁸, R⁹ and R¹⁰ and the group (Z) are of the same meaning as previously stated hereinabove for general formula (I); and

30

(U) is hydrogen or a linear or branched C₁-C₁₀ alkyl group

5 A preferred embodiment of the invention described herein entails a general formula (IV) compound in which (Z) is a hydrogen atom or a $-\text{COOC}(\text{CH}_3)_3$ group; (U) is a hydrogen atom; and $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9$ and R^{10} are the same or different and represent a hydrogen atom or a group selected between $-\text{OCH}_3$ or $-\text{OH}$.


10 A more preferred embodiment of the invention described herein entails a general formula (IV) compound selected, but without limitation, from among the following group: 2-(2,5-dihydroxyphenyl)-1*H*-indole-4,6-diol; 4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-indole; 4,6-Dimethoxy-2-(2,5-dimethoxyphenyl)-1*H*-indole-1-tert-butyl carboxylate; 4,6-Dimethoxy-2-(2,5-dimethoxyphenyl)-1*H*-indole; and 4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-indole-1-tert-butyl carboxylate.

15 The term "analogs" means, in this description, compounds of a similar structure, in other words, is bearing a similarity on the periphery of said molecules.


20 As is shown in Fig. 1, in the substituted trans-stilbenes, the distances between the quaternary aromatic atoms which bond the phenyl groups to the central group are on the order of 3.82 Å, a value within a mid-range as compared to that calculated for *N*-benzylidene anilines I (ca. 3.74 Å, Fig. 1B), 2,4-diaryl-1*H*-pyrroles (ca. 5.06 Å, Fig. 1C) and 2-aryl-1*H*-indoles (each 3.71 Å, Fig. 1D). Likewise, some hypothetical hydroxyl or alkoxy groups in a relative arrangement similar to that of the trans-resveratrol are spaced at the intervals of 10.16-8.78 Å and 9.39-7.73 Å for compounds I, II and III, values which encompass those of the resveratrol proper (8.85 Å and 8.55 Å respectively, Fig.1A). Therefore, the compounds of the invention make it possible to extend the therapeutical applications of the Trans-stilbenes on broadening the geometric parameters of the pharmacophore and to provide the possibility of optimizing interactions of major importance for the desired pharmacological activity.

35 The compounds described are of the following structural formula:


5-((E)-(4-Hydroxyphenylimino)methyl)benzene-1,3-diol, referred to hereinafter as "Azaresveratrol":



5 3,5-bis(3,5-Dihydroxyphenyl)-1*H*-pyrrole-2-methyl carboxylate, referred to hereinafter as "JE2:2":




3,5-bis(3,5-Dimethoxyphenyl)-1*H*-pyrrole-2-methyl carboxylate, referred to hereinafter as "JEM2:2-01":




10 5-(3,5-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-1*H*-pyrrole-2-methyl carboxylate, referred to hereinafter as "JE2:1":


14




5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrole-2-methyl carboxylate:




5 3-(3,5-Dihydroxyphenyl)-5-(4-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate, referred to hereinafter as "JE1:2":




5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrole-2-methyl carboxylate:




3,5 acid 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid:



5 3-(4-methoxyphenyl)-5-(dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid,
referred to hereinafter as "JEM2:1-02":




5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-carboxylate:




3,5 acid 3,5-bis (3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate:

16




5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-methyl carboxylate:




5

3,5-bis (3,5-dimethoxyphenyl)-4-nitro-1H-pyrrole-2methyl carboxylate:




10


2-(2,5-Dihydroxyphenyl)-1*H*-indole-4,6-diol, referred to hereinafter as "YEF05H":




4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-indole, referred to hereinafter as "YEF07":




5 4,6-Dimethoxy-2-(2,5-dimethoxyphenyl)-1*H*-indole:



4,6-Dimethoxy-2-(2,5-dimethoxyphenyl)-1*H*-indole-1-*tert*-butyl carboxylate, referred to hereinafter as "YEF07B":




10 4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-indole-1-*tert*-butyl carboxylate, referred to hereinafter as "YEF05B":



A second aspect of the invention described herein is the method for obtaining the general formula (II) compound, which entails reacting in the presence or absence of an organic solvent:

- 5 i) an aromatic aldehyde suitably substituted for alkoxy or hydroxyl groups of the following formula (V),




(V)

wherein:

- 10 R¹, R², R³, R⁴ and R⁵ are of the same meaning as previously stated hereinabove;

- ii) an aniline of formula (VI) similarly substituted



(VI)


- 15 wherein: R⁶, R⁷, R⁸, R⁹ and R¹⁰ are of the same meaning as previously stated hereinabove.

A preferred embodiment of the method for obtaining the formula (II) compound employs a drying agent selected, without limitation, between
20 either a suitable anhydrous salt or molecular sieve.

After eliminating the solvent and the drying agent, in the event that either one thereof is used, the resulting reaction mixture is purified by means of crystallization in the suitable solvent known by any expert on the subject.

A third aspect of the invention described herein provides a method for obtaining the formula (III) compound which entails reacting:

i) an (E) or (Z)-configuration imine of the following formula (VII):




5

(VII)

wherein: R^1 , R^2 , R^3 , R^4 and R^5 are of the same meaning as previously stated hereinabove, and R^{11} represents an alkyl (C_1 - C_{10}), preferably methyl, an aryl or an heteroaryl group;

ii) an (E) or (Z)-configuration nitroalkene of the formula (VIII):



10

(VIII)


where: R^6 , R^7 , R^8 , R^9 and R^{10} are of the same meaning as previously stated hereinabove;

15 iii) a metallic salt, selected, without limitation, from among lithium perchlorate, silver perchlorate or silver acetate; and


iv) a tertiary organic base selected from among the aliphatic bases with C_3 - C_{10} carbons or alkane-aromatic bases with C_9 - C_{15} carbons.

20 The reaction mixture can be made by means of microwave radiation or by adding one of the components to the other three, in an organic solvent and at the temperature of -25 °C to $+25$ °C, preferably at temperatures nearing $+25$ °C.

The completion of the cycloaddition reaction results in obtaining a mixture of 2-alkoxycarbonyl pyrroleidines corresponding to the substitutes selected for each individual reaction. Said mixture is dissolved in a cyclic ether such as high-boiling-point acyclic or tetra-hydrofurane such as diethylene glycol dimethyl ether, also known as "diglyme" and an oxidizing agent added such as manganese dioxide, hydrogen peroxide or 2,3-dichloride-5,6-dicyano-1,4-benzoquinone. After a certain length of time at temperatures ranging from +60 °C to +250 °C, the corresponding mixture is obtained comprised of 2-alkoxycarbonyl-*NH*-pyrrole (IX) and 2-alkoxycarbonyl-4-nitro-*NH*-pyrrole (X) the components of which can be separated by means of fractioned crystallization or chromatography:



(IX)



(X)

These (IX and (X) compounds pertain to the family of compounds of general formula (III) included in the invention described herein, in the particular cases in which (Y) is NO₂ or H; (W) is COOR¹¹; (Z) is H and R¹-R¹⁰ may be the same or different and are selected from among a hydrogen atom or a group selected between either alkoxy (-OR) or hydroxyl (-OH), where at least three of these substitutes are either alkoxy and/or hydroxyl;

For all of the other cases, the starting compounds are (IX) and (X), and the following chemical transformations are carried out:

To obtain the general formula (III) compounds, wherein (Y) is NH₂ and the derivatives thereof, the nitro group is reduced to the amine group preferably by reacting the corresponding nitrocompound with tin dichloride at temperatures ranging from +25 °C to +90 °C. Following the purification of the corresponding primary amine, this amine may be transformed into derivatives of the substituted amine, amide or ammonium salt type by means of conventional processes.

To obtain the formula (III) compounds wherein (W) is COOH, the hydrolysis of the ester function present in the compounds (IX) and (X) is preferably achieved by means of the treatment thereof with sodium or lithium hydroxide in a mixture of water and dimethoxyethane.

To obtain the formula (III) compounds wherein (W) is H, the decarboxylation of the carboxylic acids obtained in the preceding paragraph hereinabove is preferably achieved by means of thermolysis at pressures ranging from 5 mm Hg to 0.01 mm Hg and at temperatures ranging from +150 °C and +250 °C.

To obtain the compounds of formula (III) wherein R¹-R¹⁰ are OH, the transformation of the methoxyl group into hydroxyl groups is preferably achieved by reacting the corresponding methoxylate compound under an inert atmosphere preferably of argon, with a solution of boron tribromide in


dichloromethane at temperatures ranging from -20°C to $+30^{\circ}\text{C}$ for 2-24 hours, following which the mixture is treated with methanol at 0°C .

To obtain the formula (III) compound where (Z) may be alkyl ($\text{C}_1\text{-C}_{10}$), aryl, O-alkyl(aryl)carbonyl or N-alkyl(aryl)-semicarbazide. The substitution of the carbon atom present in the (IX) and (X) compounds is achieved by means of conventional alkylation and acylation methods. In the cases in which inertia is observed in the acylation, this may be facilitated by means of the use of anhydrides a catalyst acylating agents, preferably 4-dimethylaminopyridine and zinc perchlorate.

A fourth aspect of the invention described herein provides a method for obtaining the formula (VI) compound, which entails reacting:

15

i) an amine of formula (XI) below,




(XI)

20

wherein: R^1 , R^2 , R^3 and R^4 are of the same meaning as previously stated hereinabove;

ii) an alpha-halocetone of formula (XII) below,



(XII)


25

wherein: (G) may be a halogen selected from chlorine, bromine and iodine;

(U) is of the same meaning as previously stated hereinabove, and R^6 , R^7 , R^8 , R^9 and R^{10} are of the same meaning as previously stated hereinabove;

- 5 iii) a tertiary amine such as N,N-dimethylaniline or any combination of aryl, heteroaryl or linear, cyclic or branched alkyl groups.

For the purposes of the invention described herein, the reaction mixture comprised of the three immediately preceding components stated
10 hereinabove can be achieved by means of microwave radiation in the absence of a solvent at a temperature ranging from +90 °C to +180 °C, preferably at temperatures nearing +150 °C, with a radiation power of 25 to 200 W, preferably employing radiation power nearing 100 W, for radiation times of 5 to 30 minutes, the preferred radiation times being of around 10
15 minutes. The radiation may be taken to atmospheric pressure or to pressures of 50 to 200 psi (Pounds/square inch). Upon completion of the reaction, general formula (XIII) 2-aryl-1H-indoles are obtained.



(XIII)

20

Said (XIII) compounds pertain to the general formula (IV) compounds included in the invention described herein, in the particular cases in which (Z) is H and R^1 - R^{10} are of the same meaning as previously stated hereinabove.

25

For all of the other cases, starting from the (XIII) compounds, the following transformations are carried out:

To obtain the formula (IV) compound wherein any of the R¹-R¹⁰ groups are OH, the transformation of the methoxyl groups into hydroxyl groups is preferably achieved by reacting the corresponding methoxylated compound under an inert atmosphere preferably of argon, with a solution of boron tribromide in dichloromethane at temperatures ranging from -20°C to +30 °C for 2-24 hours, following which the mixture is treated with methanol at 0°C.

To obtain the formula (IV) compound wherein (Z) can be alkyl (C₁-C₁₀), aryl, O-alkyl(aryl)carbamoyl or N-alkyl(aryl)-semicarbazide: the substitution of the hydrogen atom present in the XIII compounds is achieved by means of conventional alkylation and acylation methods. In those cases in which inertia is observed in the acylation, the acylation can be facilitated by means of employing anhydrides as catalyst acylating agents, preferably 4-dimethylaminopyridine and zinc perchlorate.

A fifth aspect of the present invention provides the use of the general formula (I) compounds for the treatment or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke and heart attack, neurodegeneration, and during organ transplantation, whose pathogenic and pathophysiological mechanisms depend on or are significantly contributed by undesirable oxidative stress, angiogenic and proliferative responses.

A sixth aspect of the invention provides the use of any of the general formula (I) compounds or combinations thereof for the preparation of a pharmaceutically-acceptable composition for the treatment and prophylaxis of diseases involving cancerigenous and inflammatory processes, more preferably, but without limitation to, the treatment of hepatic metastasis.

One embodiment of the preparation of a composition may be, without being limited to, that of a composition which includes at least one of the general formula (II) compounds and one or more pharmaceutically-acceptable excipients. A composition may likewise be prepared for the formula (III) and

(IV) compounds. The formula (II), (III) and (IV) compounds of the invention described herein may be administered both as a pure substance as well as in the form of pharmaceutical formulations, although the administration of the combined-form composition is preferable.

5

Another aspect of the invention described herein provides a pharmaceutical composition which includes:

- i) at least one general formula (I) compound, preferably general formula (II), (III) or (IV), or any combination thereof:
- 10 ii) pharmaceutically-acceptable vehicles; and
- iii) additionally, a therapeutically-active substance

The term "pharmaceutically-acceptable vehicle" is understood as employed in the invention described herein as one or more excipients and/or carrier substances or auxiliary substances which are pharmaceutically or pharmacological tolerable, such that they may be combined with other components in the formulation or preparation and will have no adverse effects on the organism treated.

20 The term "therapeutically-active substance" is understood as employed in the invention described herein, as any substance synergistically interacting with resveratrol, such as, but not limited to, other polyphenols such as quercetin.


25 The pharmaceutical compositions include, but are not limited to, those which are suitable for oral or parenteral (including subcutaneous, intradermic, intramuscular and intravenous) administration, although the best way of administering depends upon the patient's condition.

30 The formulations may be in single-dose form and be prepared in accordance with methods known by any expert on the subject in the field of pharmacology. The quantities of active substances to be administered may vary in terms of the individual aspects of the therapy.

35 The following examples and figures provided in following serve to illustrate yet not limit the invention described herein.


EXAMPLES OF EMBODIMENT

5 Example 1.- Preparation of 5-((E)-(4-Hydroxyphenylimine)methyl)benzene-1,3-diol, of the following structural formula:




10 Anhydrous magnesium sulfate was added to a suspension of dry dichloromethane (5 ml) of 4-aminophenol (0.109 g, 1 mmol) and of 3,5 dihydroxybenzaldehyde (0.138 g, 1 mmol). The resulting mixture was agitated at ambient temperature for 3 hours. In following, the solvent was evaporated a low pressure and ethanol (5 mL) is added to the resulting residue. The mixture was heating to boiling and then filtered. The filtrate
15 was evaporated under low pressure to yield a residue which was ground to a minimal quantity of cold ethanol, thus yielding 5-((E)-(4-Hydroxyphenylimine)methyl)benzene-1,3-diol. Yield: 100 %; p. f. (°C) 162 (desc.) .; IR (KBr) 3494, 3287, 1631, 1598, 1508, 1461, 1339, 1273, 1155 cm^{-1} ; ^1H NMR (300 MHz, DMSO- d_6) δ 9.44 (s, 1H), 9.42 (s, 2H), 8.38 (s, 1H), 7.15 (d, $J=7.8$ Hz, 2H), ^{13}C NMR (63 MHz, DMSO- d_6) δ 158.6, 157.4,
20 156.2, 142.6, 138.4, 122.5, 115.7, 106.4, 105.3. Calc. Analysis for $\text{C}_{13}\text{H}_{11}\text{NO}_3$: C, 68.11; H, 4.84; N, 6.11. Found: C, 68.76; H, 4.92; N, 6.21 %.

25 Example 2.- Preparation of 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate, of the following structural formula:



and of 3,5-bis(3,5-dimethoxyphenyl)-4-nitro-1H-pyrrole-2-methyl carboxylate, of the following structural formula:




- 5 In a spherical flask, (3,5-dimethoxybenzylidene)amine)methyl acetate (2.0 g, 8.4 mmoles) was dissolved in 84 ml of CH₃CN, then adding 1.2 ml (1.25 mmoles) de triethylamine, 1,3-dimethoxy-5-(2-nitrovinyl)benzene (1.8 g, 8.4 mmoles) and 0.21 g (1.25 mmoles) of AgOAc. The progress of the reaction was monitored by means of thin-layer chromatography. Following
- 10 completion of the reaction (approx. 5 hours), the mixture was filtered through a celite bed and the filtrate washed with an aqueous NH₄Cl solution (2 x 84 ml) and H₂O (2 x 84 ml), was then dried on anhydrous Na₂SO₄ and evaporated at low pressure. The crude portion was purified by means of pressurized chromatography column (AcOEt/Hx). 1.8 g (4 mmoles) of the oil
- 15 obtained was dissolved in 40 ml of 2-methoxyethylether under argon atmosphere. In following, 3.5 g (40 mmoles) MnO₂ were added and agitated to reflux for 48 hours. The reaction mixture was filtered through celite and the filtrate evaporated at low pressure. The products were separated by means of flash column chromatography, obtaining 3,5-bis(3,5-
- 20 dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate and 3,5-bis(3,5-dimethoxyphenyl)-4-nitro-1H-pyrrole-2-methyl carboxylate.

3,5-bis(3,5-dimethoxyphenyl)-4-nitro-1H-pyrrole-2-methyl carboxylate:


Yield. 25% ; p.f. 139-141°C; IR 3447, 3246. 1698, 1592, 1507, 1211, 1161 cm^{-1} ; $^1\text{H-RMN}$ (δ ppm, CDCl_3) 9,42 (s, 1H), 6.70 (d, 2H, $J= 2,3$ Hz), 6.56 (t, 1H, $J= 82,2$ Hz), 6.50 (s, 3H), 3.82 (s, 6H), 3.69 (s, 3H); $^{13}\text{C-RMN}$ (δ ppm, CDCl_3) 161.3, 161.1, 160.5, 134.1, 133.9, 133.1, 130.6, 124.4, 118.4, 108.3, 107.2, 102.6, 100.7, 55.9, 55.7, 52.5. Calc. Analysis for $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O}_8$: C, 59.73; H, 5.02; N, 6.33. Found: C, 59.41; H, 4.73; N, 6.36 %.

3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate: Yield: 31% ; p.f. 113-115°C; IR 3276, 1668, 1608, 1156 cm^{-1} ; $^1\text{H-RMN}$ (δ ppm, CDCl_3) 9.28 (s, 1H), 6.77 (d, 2H, $J= 2,3$ Hz), 6.71 (d, 2H, $J= 2,2$ Hz), 6.60 (d, 2H, $J=3,1$ Hz), 6.60 (d, 2H, $J=3,1$ Hz), 6.46 (t, 1H, $J=2,3$ Hz), 6.44 (t, 1H, $J=2,2$ Hz), 3.84 (s, 6H), 3.82 (s, 3H); $^{13}\text{C-RMN}$ (δ ppm, CDCl_3) 161.9, 161.7, 160.5, 137.1, 135.7, 133.5, 133.1, 118.6, 110.6, 107.9, 103.4, 100.4, 100.0, 55.9, 55.7, 51.9. Calc. Analysis for $\text{C}_{22}\text{H}_{23}\text{N}_2\text{O}_6$: C. 66.49; H. 5.84; N. 3.52. Found: C. 66.13; H. 5.47; N, 3.66 %.

Example 3.- Preparation of 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrole-2-methyl carboxylate, of the following structural formula:



and of 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-methyl carboxylate, of the following structural formula:



Both compounds were prepared and separated by means of a procedure


similar to that described in Example 2 hereinabove.

5 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-methyl
carboxylate: Yield: 20% ; p.f. 194-145°C; IR 3266, 1683, 1597, 1507, 1276,
1211, 1166 cm⁻¹; ¹H-RMN (δ ppm. CDCl₃) 9.42 (s. 1H). 7.32 (d. 2H. J= 8.3
Hz). 6.96 (d. 2H. J= 8.3 Hz). 6.71 (s. 2H). 6.58 (s. 1H). 3.87 (s. 3H). 3.84
(s. 3H). 3.71 (s. 3H); ¹³C-RMN (δ ppm. CDCl₃) 161.4, 161.2, 159.7, 134.4,
133.9, 131.4, 130.6, 127.6, 123.2, 118.3, 113.5, 107.2, 103.5, 102.4, 55.9,
55.5, 52.4. Calc. Analysis for C₂₁H₂₀N₂O₇: C. 61.16; H. 4.90; N. 6.80.
10 Found: C. 61.47; H. 4.92; N. 7.00 %.

5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrrole-2-methyl
carboxylate: Yield: 35% ; p.f. 123-125°C; IR 3286, 1678, 1211 cm⁻¹; ¹H-
RMN (δ ppm, CDCl₃) 9.24 (s, 1H), 7.55 (d, 2H, J= 8.6 Hz), 6.95 (d, 2H, J=
15 8.6 Hz), 6.72 (s, 2H), 6.58 (d, 2H, J=2.9 Hz), 6.45 (s, 1H) , 3.86 (s, 9H),
3.82 (s, 3H); ¹³C-RMN (δ ppm, CDCl₃) 161.9, 161.7, 159.2, 135.7, 133.7,
133.3, 130.8, 127.7, 118.2, 113.6, 110.4, 103.5, 100.3, 55.8, 55.6, 51.7.
Calc. Analysis for C₂₁H₂₁NO₅: C, 68.65; H, 5.77; N, 3.81. Found: C, 68.35;
H, 6.00; N, 3.95 %.


20

Example 4.- Preparation of 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-
1H-pyrrole-2-methyl carboxylate, of the following structural formula:



25 and of 5-(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-
methyl carboxylate, of the following structural formula:

30




Both compounds were prepared and separated by means of a procedure similar to that described in Example 2.

5 3-(3,5-dimethoxyphenyl)-5-(4-methoxyphenyl)-4-nitro-1H-pyrrole-2-methyl
 carboxylate: Yield: 20% ; p.f. 176-178°C; IR 3286, 1683, 1618, 1507, 1311
 cm⁻¹; ¹H-RMN (δ ppm, CDCl₃) 9.20 (s, 1H), 7.56 (d, 2H, J= 8.7 Hz), 7.02 (d,
 2H, J= 8.7 Hz), 6.52 (s, 3H), 3.89 (s, 3H), 3.82 (s, 6H), 3.74 (s, 3H); ¹³C-
 10 RMN (δ ppm, CDCl₃) 161.1, 160.2, 134.7, 133.2, 130.5, 127.4, 120.9,
 118.0, 114.4, 108.1, 100.4, 100.3, 55.6, 55.5, 52.2. Calc. Analysis for
 C₂₁H₂₀N₂O₇: C, 61.16; H, 4.90; N, 6.80. Found: C, 61.20; H, 5.15; N, 6.87
 %.

15 3-(3,5-dimethoxyphenyl)-5-(4-methoxyphenyl)-1H-pyrrole-2-methyl
 carboxylate: Yield: 28% ; p.f. 149-150°C; IR 3326, 1673, 1151 cm⁻¹; ¹H-
 RMN (δ ppm, CDCl₃) 9.18 (s, 1H), 7.51 (d, 2H, J= 8.7 Hz), 6.96 (d, 2H, J=
 8.7 Hz), 6.77 (d, 2H, J=2.5 Hz), 6.53 (d, 2H, J=2.5 Hz), 6.45 (s, 1H) , 3.84
 (s, 3H), 3.82 (s, 6H), 3.80 (s, 3H); ¹³C-RMN (δ ppm, CDCl₃) 161.8, 160.3,
 159.7, 135.1, 135.8, 133.5, 126.3, 123.9, 117.8, 114.6, 109.3, 107.7, 99.8,
 20 55.5, 51.5. Calc. Analysis for C₂₁H₂₁NO₅: C, 68.65; H, 5.77; N, 3.81. Found:
 C, 68.52; H, 5.42; N, 4.08 %.

Example 5.- Preparation of 3,5-bis(3,5-Dihydroxyphenyl)-1H-pyrrole-2-
 methyl carboxylate, of the following structural formula:



25

In a spherical flask cooled to 0°C and under argon atmosphere, 0.2 g (0.5 mmoles) of 3,5-bis(3,5-Dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate (Prepared as stated in Example 2) were dissolved in 12 ml of dry dichloromethane. In following, 6 ml of BBr₃ (1 M in dichloromethane) were added drop by drop and agitated to ambient temperature for 16 hours. The reaction was halted by adding MeOH at 0°C drop by drop. The resulting solid was filtered and purified by means of pressurized column chromatography. (Eluent: MeOH/CH₂Cl₂) obtaining the compound 3,5-bis(3,5-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate.


10

3,5-bis(3,5-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate: Yield: 69% ; p.f. 233-235°C; IR 3427, 1618 cm⁻¹; ¹H-RMN (δ ppm, DMSO-d₆) 11.2 (s, 1H), 9.20 (s, 2H), 9.03 (s, 2H), 7.04 (s, 1H), 6.52 (s, 1H), 6.48 (s, 2H), 6.40 (s, 2H), 6.09 (s, 1H), 6.02 (s, 1H), ; ¹³C-RMN (δ ppm, DMSO-d₆) 161.0, 157.7, 157.2, 137.2, 136.3, 133.4, 127.1, 122.4, 117.1, 115.6, 108.5, 107.7, 101.3, 51.0. Calc. Analysis for C₁₈H₁₅NO₆: C, 66.46; H, 4.65; N, 4.31. Found: C, 66.13; H, 4.57; N, 4.36 %.

15

Example 6.- Preparation of 5-(3,5-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate, of the following structural formula:

20




This compound was prepared and purified according to a procedure similar to that described in Example 5.

5-(3,5-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate: Yield: 63% ; p.f. breaks down; IR 3537, 3397, 3316, 1673, 1597, 1271, 1161 cm⁻¹; ¹H-RMN (δ ppm, DMSO-d₆) 11.6 (s, 1H), 9.41 (s, 1H), 9.34 (s, 2H), 7.34 (d, 2H, J=8.5 Hz), 6.74 (d, 2H, J=8.5 Hz), 6.67 (d, 2H, J=2.1 Hz), 6.46 (d, 2H, J=2.1 Hz), 6.19 (s, 1H), 3.68 (s, 3H); ¹³C-RMN (δ ppm, DMSO-d₆) 161.0, 158.6, 156.5, 136.2, 132.9, 130.4, 126.0, 117.4,

25

114.6, 109.4, 104.0, 102.2, 50.9. Calc. Analysis for $C_{18}H_{15}NO_5$: C, 66.46; H, 4.65; N, 4.31. Found: C, 66.60; H, 4.41; N, 4.26 %.


5 Example 7.- Preparation of 3-(3,5-Dihydroxyphenyl)-5-(4-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate, of the following structural formula:



This compound was prepared and purified according to a procedure similar to that described in Example 5.

10 3-(3,5-Dihydroxyphenyl)-5-(4-hydroxyphenyl)-1H-pyrrole-2-methyl carboxylate: Yield: 66% ; p.f. 234-236 °C; IR 3326, 1678, 1608, 1281, 1161 cm^{-1} ; 1H -RMN (δ ppm, DMSO- d_6) 11.6 (s, 1H), 9.64 (s, 1H), 9.16 (s, 2H), 7.66 (d, 2H, J=8.6 Hz), 6.78 (d, 2H, J=8.6 Hz), 6.45 (d, 2H, J=2.3 Hz), 6.37 (d, 2H, J=2.3 Hz), 6.19 (s, 1H), 3.69 (s, 3H); ^{13}C -RMN (δ ppm, DMSO- d_6) 161.0, 157.7, 157.2, 137.2, 136.3, 133.4, 127.1, 122.4, 117.1, 115.6, 108.5, 107.7, 101.3, 51.0. Calc. Analysis for $C_{18}H_{15}NO_5$: C, 66.46; H, 4.65; N, 4.31. Found: C, 66.67; H, 4.61; N, 4.23 %.

Example 8.- Preparation of 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid, of the following structural formula:



20

In a spherical flask, 0.45 g (1.1 mmoles) of 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate (Prepared as stated in Example 2), 11 ml of 10% $NaOH$ and 28 ml of ethanol were agitated for 3 hours to reflux. After cooling the reaction flask, the reaction crude was neutralized with HCl 1M.

In following, the ethanol was evaporated at low pressure and the resulting aqueous phase was washed with AcOEt. Lastly, the organic phase was dried on Na₂SO₄ and was evaporated at low pressure, obtaining the compound 3,5-bis(3,5-dihydroxyphenyl)-1H-pyrrole-2-carboxylic acid.


5

3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid: Yield: 98% ; p.f. 169-171°C; IR 3316, 1653, 1608, 1196, 1156 cm⁻¹; ¹H-RMN (δ ppm, CDCl₃) 11.0 (s, 1H), 9.37 (s, 1H), 6.80 (d, 2H, J=2.0 Hz), 6.74 (d, 2H, J=2.0 Hz), 6.65 (d, 2H, J=2.8 Hz), 6.52-6.43 (m, 2H), 3.86 (s, 6H), 3.84 (s, 6H); ¹³C-RMN (δ ppm, CDCl₃) 165.0, 161.6, 160.5, 136.7, 136.5, 135.1, 132.7, 117.5, 110.9, 107.8, 103.5, 100.6, 100.2, 55.7, 55.6. Calc. Analysis for C₂₁H₂₁NO₆: C, 65.79; H, 5.52; N, 3.65. Found: C, 65.71; H, 5.27; N, 3.55 %.

10

Example 9.- Preparation of 3-(4-methoxyphenyl)-5-(dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid, of the following structural formula:

15




This compound was prepared and purified according to a procedure similar to that described in Example 8.

20

3-(4-methoxyphenyl)-5-(dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid: Yield: 85%; p.f. 152-153 °C; IR 3475, 3306, 1648, 1597, 1251, 1211, 1156 cm⁻¹; ¹H NMR (δ ppm, CDCl₃) 11.3 (s, 1H), 9.30 (s, 1H), 7.56 (d, 2H, J = 8.5 Hz), 6.94 (d, 2H, J = 8.5 Hz), 6.72 (d, 2H, J = 1.7 Hz), 6.60 (d, 1H, J = 2.6 Hz), 6.46 (s, 1H), 3.85 (s, 9H); ¹³C NMR (δ ppm, CDCl₃) 161.2, 158.7, 137.9, 133.2, 126.7, 125.7, 125.5, 115.3, 114.6, 103.7, 103.3, 99.1, 55.5. Calc. Analysis for C₂₀H₁₉NO₅: C, 67.98; H, 5.42; N, 3.96. Found: C, 67.88; H, 5.51, N, 4.00;

25

Example 10.- Preparation of 2,4-bis(3,5-dihydroxyphenyl)-1H-pyrrole, of the following structural formula:




5 0.1 g (0.26 mmoles) of the 3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid (Prepared as stated in Example 8) were heated for 1 hour to 180-200°C at a pressure of 1.2 mmHg. Upon completion of the reaction, the crude was cooled, obtaining 2,4-bis(3,5-dihydroxyphenyl)-1H-pyrrole, which was purified by means of column chromatography (Eluent: AcOEt/hexanes).

10

3,5-bis(3,5-Dimethoxyphenyl)-1H-pyrrole: Yield: 92% ; p.f. 124-125°C; IR 3427, 1597, 1212, 1161 cm^{-1} ; $^1\text{H-RMN}$ (δ ppm, CDCl_3) 8,43 (s, 1H), 7,08 (s, 1H), 6,75 (s, 1H), 6,70 (d, 2H, $J=2,2$ Hz), 6,63 (d, 2H, $J=2,1$ Hz), 6,35 (t, 1H, $J=2,1$ Hz), 6,33 (t, 1H, $J=2,2$ Hz), 3,82 (s, 12H); $^{13}\text{C-RMN}$ (δ ppm, CDCl_3)
 15 161,5, 161,2, 137,7, 134,5, 133,1, 126,7, 116,0, 104,7, 103,7, 102,5, 98,7, 98,1, 55,6, 55,5. Calc. Analysis for $\text{C}_{20}\text{H}_{21}\text{NO}_4$: C, 70,78; H, 6,24; N, 4,13. Found: C, 70,65; H, 6,07; N, 4,20 %.

20

Example 11.- Preparation of 4-amino-3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate, of the following structural formula:




Seven milliliters (7 ml) of a $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ 1M in DMF were added to 0.2 g (0.45 mmol) of 3,5-bis(3,5-dimethoxyphenyl)-4-nitro-1H-pyrrole-2-methyl

carboxylate (Prepared as stated in Example 2) and was agitated at 50°C for 16 hours. Upon completion of the reaction, 4.5 ml of AcOEt and 10% aqueous Na₂CO₃ solution were added until no further precipitate appeared. The organic phase was separated and washed with saturated Na₂CO₃ solution and water. After drying on anhydrous Na₂SO₄ and evaporating at low pressure, the crude portion was purified by means of pressure column chromatography (Eluent: AcOEt/hexanes) obtaining 4-amino-3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate.

4-Amino-3,5-bis(3,5-dimethoxyphenyl)-1H-pyrrole-2-methyl carboxylate:
Yield: 81% ; p.f. 74-76°C; IR 3417, 3346. 1678, 1597, 1211, 1151 cm⁻¹; ¹H-RMN (δ ppm, CDCl₃) 8.74 (s, 1H), 6.74 (d, 2H, J= 2.2 Hz), 6.60 (d, 2H, J=2.1 Hz), 6.46 (t, 1H, J= 2.1 Hz), 6.40 (t, 1H, J=2.0 Hz), 3.84 (s, 6H), 3.81 (s, 6H), 3.73 (s, 3H); ¹³C-RMN (δ ppm, CDCl₃) 161.6, 160.6, 135.0, 133.6, 129.5, 121.6, 120.5, 116.7, 108.2, 103.7, 99.8, 99.2, 55.6, 55.5, 51.5. Calc. Analysis for C₂₂H₂₄N₂O₆: C, 64.07; H, 5.87; N, 6.79. Found: C, 63.91; H, 5.74; N, 6.57 %.


Example 12.- Preparation of 4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole, of the following structural formula:



0.32 g (2.1 mmoles) of 3,5-dimethoxyaniline, 0.26 g (1.0 mmol) of 2-bromo-1-(3,5-dimethoxyphenyl)ethanone and 0.42 ml (3.3 mmol) of N,N-dimethylaniline were placed in a vial. The vial was placed inside a monomode microwave reactor and was radiated at a power of 100 W, at a temperature of 150 °C for 10 minutes. After cooling the reaction vial, the mixture was dissolved in AcOEt, was washed with an aqueous HCl 2N solution, was dried on anhydrous Na₂SO₄ and was evaporated at low pressure. The crude portion was purified by means of pressure column chromatography (Eluent: AcOEt/hexanes) obtaining 4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole.

4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole: Yield: 80% ; p.f. 126-128°C; IR 3407, 1608, 1206, 1161 cm^{-1} ; $^1\text{H-RMN}$ (δ ppm, CDCl_3) 8.18 (s, 1H), 6.82 (s, 1H), 6.73 (d, 2H, $J=1.8$ Hz), 6.49 (s, 1H), 6.38 (s, 1H), 6.22 (s, 1H), 3.92 (s, 3H), 3.83 (s, 9H); $^{13}\text{C-RMN}$ (δ ppm, CDCl_3) 161.4, 158.2, 153.9, 138.3, 135.3, 134.7, 114.6, 103.1, 99.4, 97.8, 92.2, 87.1, 55.8, 55.6. Calc. Analysis for $\text{C}_{18}\text{H}_{19}\text{NO}_4$: C, 68.99; H, 6.11; N, 4.47. Found: C, 68.92; H, 5.84; N, 4.46 %.


Example 13.- Preparation of 4,6-dimethoxy-2-(2,5-dimethoxyphenyl)-1H-indole, of the following structural formula:



The compound stated in the heading above was prepared and purified according to a procedure similar to that described in Example 11.

4,6-dimethoxy-2-(2,5-dimethoxyphenyl)-1H-indole: Yield: 61% ; p.f. 148-150°C; IR 3407, 1542, 1487, 1211, 1141 cm^{-1} ; $^1\text{H-RMN}$ (δ ppm, CDCl_3) 9.62 (s, 1H), 7.32 (d, 2H, $J=3.0$ Hz), 6.92 (d, 2H, $J=8.9$ Hz), 6.90 (d, 1H, $J=1.3$ Hz), 6.76 (dd, 1H, $J=8.9$, $J'=3.0$ Hz), 6.52 (s, 1H), 6.21 (d, 1H, $J=1.3$ Hz), 3.94 (s, 6H), 3.84 (s, 3H), 3.81 (s, 3H); $^{13}\text{C-RMN}$ (δ ppm, CDCl_3) 157.7, 154.3, 153.5, 149.9, 137.4, 133.1, 121.7, 113.5, 113.4, 112.3, 97.2, 91.7, 86.8, 56.6, 55.8, 55.7, 55.4. Calc. Analysis for $\text{C}_{18}\text{H}_{19}\text{NO}_4$: C, 68.99; H, 6.11; N, 4.47. Found: C, 68.72; H, 6.44; N, 4.45 %.

Example 14.- Preparation of 4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole-1- tert-butyl carboxylate, of the following structural formula:




25

0.20 g (0.92 mmol) of Boc_2O and 0.009 g (0.071 mmol) of 4-

dimthylaminopyridine were added to a solution of 0.21 g (0.68 mmol) of 4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole (Prepared according to the procedure described in Example 11) in 8.2 ml of acetonitril and was agitated at ambient temperature for 3 hours. In following, the solvent was evaporated at reduced pressure and the resulting product was purified by means of pressure column chromatography (Eluent: AcOEt/hexanes), obtaining the compound 4,6-dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole-1-tert-butyl carboxylate.

4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1H-indole-1-tert-butyl carboxylate:
Yield: 60% ; p.f. 92-94°C; IR 1733, 1613, 1587, 1311, 1151 cm^{-1} ; ^1H -RMN (δ ppm, CDCl_3) 7.38 (d, 1H, J=1.6 Hz), 6.59 (s, 1H), 6.54 (d, 1H, J=2.3 Hz), 6.44 (t, 1H, J=2.3), 6.35 (d, 1H, J=1.6 Hz), 3.89 (s, 3H), 3.88 (s, 3H), 3.79 (s, 6H), 1.33 (s, 9H); ^{13}C -RMN (δ ppm, CDCl_3) 160.4, 159.3, 153.3, 150.6, 139.3, 137.6, 137.2, 113.8, 107.1, 106.8, 99.9, 94.8, 91.6, 83.5, 56.0, 55.6, 27.8. Calc. Analysis for $\text{C}_{23}\text{H}_{27}\text{NO}_6$: C, 66.81; H, 6.58; N, 3.39. Found: C, 66.67; H, 6.44; N, 3.44 %.

Example 15.- Preparation of 4,6-dimethoxy-2-(2,5-dimethoxyphenyl)-1H-indole-1-tert-butyl carboxylate, of the following structural formula:




The compound stated in the heading above was prepared and purified by means of a procedure similar to that described in Example 13.

4,6-Dimethoxy-2-(2,5-dimethoxyphenyl)-1H-indole-1-tert-butyl carboxylate:
Yield: 86% ; p.f. 56-58°C; IR 1783, 1497, 1311, 1221, 1151 cm^{-1} ; ^1H -RMN (δ ppm, CDCl_3) 7.39 (d, 1H, J=1.5 Hz), 6.94 (d, 1H, J=3.0 Hz), 6.84 (dd, 1H, J=8.8 Hz, J'=3.0 Hz), 6.77 (d, 1H, J=8.8), 6.54 (s, 1H), 6.33 (d, 1H, J=1.5 Hz), 3.88 (s, 6H), 3.78 (s, 3H), 3.67 (s, 3H), 1.30 (s, 9H); ^{13}C -RMN (δ ppm,

CDCl₃) 159.0, 153.6, 153.2, 151.7, 150.5, 138.7, 134.2, 125.9, 116.2, 113.6, 111.1, 106.5, 94.4, 91.5, 82.8, 56.0, 55.9, 55.6, 27.7. Calc. Analysis for C₂₃H₂₇NO₆: C, 66.81; H, 6.58; N, 3.39. Found: C, 66.81; H, 6.24; N, 3.51 %.

5

Example 16.- Preparation of 2-(2,5-dihydroxyphenyl)-1H-indole-4,6-diol, of the following structural formula:



10 In a spherical flask cooled to 0°C and under argon atmosphere, 0.2 g (0.5 mmol) of 4,6-dimethoxy-2-(2,5-dimethoxyphenyl)-1H-indole-1-tert-butyl carboxylate (Prepared as described in Example 14) were dissolved in 12 ml of dry dichloromethane. In following, 6 ml of BBr₃ (1 M in dichloromethane) were added drop by drop and agitated to ambient temperature for 16 hours.

15 The reaction was halted by adding MeOH drop by drop at 0°C. The resulting solid was filtered and was purified by means of pressure column chromatography (Eluent: MeOH/CH₂Cl₂) obtaining the compound 2-(2,5-dihydroxyphenyl)-1H-indole-4,6-diol.

20 2-(2,5-Dihydroxyphenyl)-1H-indole-4,6-diol: Yield: 52% ; p.f. breaks down; IR 3363, 1612, 1456, 1207 cm⁻¹; ¹H-RMN (δ ppm, DMSO-d₆) 10.46 (s, 1H), 9.14 (s, 1H), 9.09 (s, 1H), 8.65 (s, 1H), 8.60 (s, 1H), 7.01 (d, 1H, J=2.8 Hz), 6.80 (d, 1H, J=1.3 Hz), 6.73 (d, 1H, J=8.6 Hz), 6.60 (dd, 1H, J=8.6 Hz, J'=2.8 Hz), 6.29 (s, 1H), 5.92 (d, 1H, J=1.3 Hz); ¹³C-RMN (δ ppm, DMSO-

25 d₆) 153.9, 150.3, 149.8, 146.3, 138.4, 131.3, 119.8, 116.8, 113.8, 112.5, 112.2, 98.4, 94.5, 88.2. Calc. Analysis for C₁₄H₁₁NO₄: C, 65.37; H, 4.31; N, 5.44. Found: C, 65.52; H, 4.36; N, 5.11 %.

30 Example 17.- Tests conducted to evaluate the *in vitro* and *in vivo* biological activity of the general formula (I) compounds:

The potential antimetastatic effect of general formula (II) compounds was studied by using an *in vivo* experimental model of inflammation and oxidative stress-dependent hepatic colonization of intrasplenically-injected B16 melanoma (MB16) cells, in which the metastasis density and volume ,
5 the type of metastasis based on the angiogenic (sinusoidal or portal) pattern thereof, the length of the angiogenic vessels within tumor nodules, the percentage of metastatic focal points with cavitation and the percentage of in situ proliferating metastatic cells were histologically determined. In following, for the purpose of studying in what stage of the development of
10 the metastasis said compounds were acting, the *in vivo* effect thereof on the hepatic retention of the tumor cells and *in vitro*, on one hand, on the production of hydrogen peroxide, adhesion and proliferation of murine B16 melanoma and human A375 melanoma cells and, on the other hand, on the migration and proliferation of primary cultures of endothelial cells and
15 hepatic stellate cells was determined.

Following an optimization of the chemical structure, the general formula (III) compounds and the general formula (IV) compounds, the chemical and configurational stability of which afford the possibility of preserving the trans
20 arrangement between the aromatic rings (A and B), see general formula (I), avoiding the possibility of isomerization and the resulting loss activity. The following *in vitro* tests were conducted with these compounds:

Tests of B16 (MB16) melanoma cell interaction with primary cultures of hepatic sinusoidal endothelium (HSE cells treated with conditioned MB16 (MC-MB16) media:

- ELISA determination of the TNF-alpha concentration in the supernatants of HSE cell cultures treated with MC-MB16.
- Determination of the production of hydrogen peroxide from HSE cells and MB16 cells.
- Cell adhesion tests of MB16 cells incubated with non-toxic concentrations of hydrogen peroxide to the immobilized recombinant VCAM-1 substrate.
- Proliferation tests of the MB16 cells treated with recombinant murine
35 IL-18.

- Enzymatic immunoassay (EIA) of PGE2 in the supernatant of the untreated and VEGF-treated HSE cells.

5 Lastly, an evaluation was made on the effect of those compounds showing greater inhibitory activity in the *in vitro* tests on the metastatic capacity of the MB16 cells by means of *in vivo* tests on the development of hepatic metastasis.

10 Example 17.a) - Tests conducted to evaluate the *in vitro* biological activity

Culture of B16 (MB16) and A375 (MA375) melanoma cells. The MB16 (B16F10 subline) murine tumor cells were cultured at 37°C, with 5% CO₂ atmosphere in Dulbecco's modified Eagle's medium (DMEM)-HCO₃⁻, penicillin (100 U/ml), streptomycin (100 µg/ml), supplemented with 5% fetal bovine serum and adjusted to pH 7.4. The cells were maintained and subcultured according to the method described by Vidal-Vanaclocha et al. (1994) [Vidal-Vanaclocha, F., Amézaga, C., Asumendi, A., Kaplanski, G. & Dinarello, C.A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. *Cancer Research*, 1994, 54, 2667-2672]. The conditioned media were obtained from subconfluent cultures maintained in absence of FBS for 24 hours.

Isolation of primary murine cultures of hepatic sinusoidal endothelial (HSE) cells. The hepatic sinusoidal cells were isolated from C57BL/6J mice (males, aged 6-8 weeks) supplied by IFFA Credo (L'Arbreole, France), followed by a purification and identification of the HSE cells following the protocol described by Vidal-Vanaclocha et al. (1993) [Vidal-Vanaclocha, F., Rocha, M., Asumendi, A. & Barbera-Guillem, E. Isolation and enrichment of two sublobular compartment-specific endothelial cell subpopulations from liver sinusoids. *Hepatology*, 1993, 18, 328-339]. Stable primary cultures of HSE cells were obtained after seeding the cells on a type I collagen substrate (Sigma Chemicals Co, St Louis, MO) , and the cultures were maintained in DMEM-HCO₃⁻, penicillin (100 U/ml), streptomycin (100 µg/ml), supplemented with 10% fetal bovine serum at 37°C with 5% CO₂ in atmosphere at 98% humidity.

Isolation of primary human cultures of hepatic sinusoidal endothelial (HSE) hepatic stellate cells (HSCs). The primary cultures of human HSE and HSC cells were obtained by non-tumoral hepatic tissue serial profusion with collagenase and pronase solutions, followed by Nycodenz gradient and seeded on 24-well plates (0.5×10^4 cells /cm²) in DMEM supplemented with 10% FBS.

MB16 cell adhesion to the monolayer of HSE cells in culture. The endothelial cells were isolated 24 hours prior to the adhesion test and were seeded on 24-well plate, maintaining them a minimum of 4 hours in serum-free medium before incubating them with DMEM in the presence or not of MC-MB16 for 8 hours. The synthesized compounds (JE2:2 see Fig. 6; JEM2:2-01 and JEM2:1-02 see Fig. 8A; YEF02, YEF03, YEF07, YEF05B, YEF07B and YEF05H see Fig. 10) were added to a 2.5 μ M concentration prior to the MC-MB16. On the other hand, the MB16 cells were marked with 40 μ g/ml from the fluorescent probe BCECF-AM (carboxyfluorescein, 2',7'-bis-(2-carboxy-ethyl)-5-(6)carboxyfluorescein aminoxymethyl ester) supplied by Molecular Probes Inc. (Oregon, USA). Afterward, a washing process was performed with DMEM-HCO₃⁻ to remove the excess fluorochromium, the number of viable cells being calculated by means of the trypan blue exclusion test and resuspended to a concentration of 2×10^5 cells/ml. Lastly, 1 ml of the MB16 cell suspension was added to each well on the primary HSE cell culture plate. The co-culture plates were incubator-incubated at 37° C for 8 minutes. The percentage of cellular adhesion was calculated by means of the a fluorescence measurement system described by Vidal-Vanaclocha et al. (1994) [Vidal-Vanaclocha, F., Amézaga, C., Asumendi, A., Kaplanski, G. & Dinarello, C.A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Research, 1994, 54, 2667-2672]. In the experiments with IL-18, the MB16 cells were incubated with 10ng/ml of IL-18 for 4 hours prior to being marked with BCECF-AM and were adhered to the HSE cell plate. The results in the figures are given as values related to the adhesion percentages of the untreated HSE cells.

MB16 and MA375 cell adhesion to immobilized VCAM-1 substrates. The

MB16 and MA375 cell adhesion tests were conducted on immobilized VCAM-1 substrates (2 µg/ml of recombinant human VCAM-1, R&D Systems, Minneapolis, MN) on 96-well plates. To avoid non-specific attachment to the plastic, 0.5% BSA dissolved in PBS was added to the wells for 2 hours at ambient temperature prior to conducting the adhesion test. The melanoma cells were preincubated with 2.5 µM of the compounds to be tested (azaresveratrol, see Table 2; JE1:2, JE2:1 and JE2:2 see Fig. 2; JEM2:2-01 and JEM2:1-02 see Fig. 7; YEF02, YEF03, YEF07, YEF05B, YEF07B and YEF05H see Fig. 9) for 30 minutes, to which 10 µM of hydrogen peroxide or 10 ng/ml of IL-18 were added, respectively for a further 2-4 hours. Afterward, the cells were washed and marked with the BCECF-AM fluorescent probe (carboxyfluorescein, 2',7'-bis-(2-carboxy-ethyl)-5-(6)carboxyfluorescein aminoxymethyl ester). Thirty minutes later, a washing process was performed to remove the excess fluorochromium, the number of viable cells being calculated by means of the trypan blue exclusion test and (5×10^4 cells/well) being added to the 96-well plate. The co-culture plates were incubator-incubated at 37°C for 1 hours. The percentage of cellular adhesion was calculated by measuring the fluorescence emitted by the adhered cells (obtained after washing the plate) with regard to the fluorescence emitted by the total number of cells added. The results in the figures are given in values related to the adhesion percentages of the untreated melanoma cells.

ELISA determination of the TNF-alpha concentration in the supernatant from MC-MB16-treated HSE cells. Primary cultured HSE cells were incubated in the presence or absence of 2.5 µM of the synthesized compounds (JEM2:2-01 and JEM2:1-02 see Fig. 8B) for 30 minutes, after which MB16-conditioned media were added. Eight (8) hours later, the supernatant from cultured endothelial cells were collected, filtered through 0.22 µm membranes and the concentration of TNF-alpha was then assayed using the ELISA test (R&D Systems).

Determination of hydrogen peroxide production from HSE and MB16 cells. Primary cultures of HSE cells were treated with 10 µg/ml of the DCFH-DA fluorescent probe for 30 minutes at 37°C and were washed to eliminate the excess fluorochromium. Afterward, fresh culture medium was added thereto

in the presence or absence of 2.5 μ M of the compounds JE1:2, JE2:1 or JE2:2 and the production of H₂O₂ over the course of time was determined (see Fig. 5). The hydrogen peroxide produced by the cells oxidizes the probe, converting it into a fluorescent molecule. Thus, the cell fluorescence produced by the accumulation of DCF made it possible to detect the intracellular production of hydrogen peroxide. In each cell well, it was possible to determine the relative fluorescence value (arbitrary units of fluorescence brightness) in relation to the quantity of hydrogen peroxide produced at different incubation times. In the experiments with MB16 cells, once the cells had been marked with the DCFH-DA probe, they were incubated for 300 minutes with 2.5 μ M of the azaresveratrol or JE2:2 compounds, 10 ng/ml of IL-18 (Fig. 4) then having been added.

In vitro Melanoma cell proliferation test. The MB16 or MA375 cells are seeded (2500 cells/well/200 μ l) in DMEM medium (Dulbecco's modified Eagle's medium) with 10% fetal bovine serum (FBS). Once adhered, they were washed to remove the FBS and fresh medium was added in the presence or absence of 2.5 μ M of the compounds to be tested. In the experiments with MA375, the compound azaresveratrol (see Table 4) was used, and in the experiments with MB16 cells, the compounds azaresveratrol, JE1:2, JE2:1 or JE2:2 (see Fig. 3) were used. Thirty (30) minutes later, 10 ng/ml of IL-18 or HSC-conditioned media (murines in the case of B16 and human ones in the case of A375) were added to some wells, and the plates were incubated for 48 hours at 37°C with 5% CO₂. Upon completion of the incubation period, the cells were fixed with 64% for 1 hours, were washed and were allowed to dry in the incubator at 50°C for 30 minutes. In following, 100 μ l/well of sulforhodamine 101 (0.4% p/v) was added and they were incubated at room temperature in the dark for 30 minutes. After washing, 200 μ l/well of Tris base 10 mM pH 10.5 was added and the fluorescence was measured by means of a 530 nm, 620 nm emission excitation filter plate fluorescence reader. The number of cells was calculated by extrapolating said fluorescence data on a standard straight line previously obtained based on the fluorescence emitted in an increasing number of cells.

35

Table 4

IN VITRO TESTS	CONTROL	TREATMENT	+ RESVERATROL	+ AZARESVERATROL
Proliferation of MA375 cells in response to human HSC soluble factors (No. cells per well)	9000 ± 60	17500 ± 50	9050 ± 100	9250 ± 65
Proliferation of MB16 cells in response to murine HSC soluble factors (No. cells per well)	16300 ± 300	21660 ± 500	16800 ± 250	16750 ± 135

5 HSC proliferation test. Primary cultured human HSC cultures were seeded (2500 cells/well/200µl) in DMEM with 10% FBS. Once adhered, they were washed to remove the FBS and were incubated with fresh medium in the presence or absence of 12.5 µM of the azaresveratrol compound (see Table 3). Thirty (30) minutes later, conditioned media obtained from MA375 cells were added to some wells, and the plates were incubated for 48 hours in humid incubator at 37°C with 5% CO₂. Upon completion of the incubation time, the cells were fixed and were processed for counting just as previously described hereinabove.

15 PGE2 determination in HSE cell supernatants (see Fig. 11). Primary cultured HSE cells were incubated in the presence or absence of increasing concentrations (1, 2.5 and 10 µM) of the compounds JE2:2, YEF07 and YEF05B for 30 minutes. In following, 10 ng/ml of recombinant murine VEGF or the same volume of saline solution was added, 4 hours after which supernatants were collected and the PGE2 concentration determined by enzymatic immunoassay (EIA) supplied by Amersham Biosciences (Uppsala, Sweden).

20 Human HSC and HSE cell migration tests (see Table 3). Primary cultured hepatic endothelial cells (25x10⁵) or hepatic stellate cells (2x10⁴) were seeded in the upper compartment of modified Boyden chambers equipped with a polycarbonate filter of an 8 µm pore size. Some cells were incubated in the presence or absence of 12.5 µM of azaresveratrol, 30 minutes prior to adding conditioned tumor medium. Twenty-four (24) hours later (in the case of the endothelial cells) or 4 hours later (in the case of hepatic star cells) the number of cells having passed through the membrane was determined. The

cells were fixed, were stained with hematoxylin eosine and were counted under the microscope (20x) in 5 fields per well.

Table 3

IN VITRO TESTS	CONTROL	TREATMENT	+ RESVERATROL	+ AZARESVERATROL
Migration of human HSC's treated with MC-MA375 (No. cells migrated per field)	10.0 ± 4	91.5 ± 19	6.5 ± 1.4	6.0 ± 1.3
Proliferation of human HSC's treated with MC-MA375 (No. cells per well)	2550 ± 22	4400 ± 30	2250 ± 100	2600 ± 60
Migration of HSE's treated with MC-MA375 (No. cells per field)	10.0 ± 4	35.0 ± 8.0	13.5 ± 5.0	15.5 ± 30

5

Example 17.b).- Tests conducted to evaluate the *in vivo* biological activity:

10

MB16 Hepatic Metastasis Test using C57 BL/6J mice(males 6-8 weeks of age) supplied by IFFA Credo (L'Arbreole, France). The care, maintenance and experimental conditions were carried out in accordance with that which is set forth under EEC Council Directive 86/609 (OJ L 358. 1, Dec. 12, 1987) and the NIH *guide for the care and use of laboratory animals* (NIH publication 85-23, 1985). In the experiments with the resveratrol and azaresveratrol compounds (Table 1), the animals (10 per group) received 1 mg/Kg/day of the compounds nasogastrically every day up to the time of sacrifice. In the experiments with the JE2:2 compound (Fig. 12), one group of mice (n=10) was given an intraperitoneal injection of 0.5 mg/kg of the JE2:2 compound dissolved in 0.1ml of PBS. The control group (n=10), was given an intraperitoneal injection of PBS. One hour later, animals were anesthetized and were intrasplenically injected with MB16 cells (3×10^5 cells/mouse). The same treatments, at the same doses, were repeated on days 2,3,4,8,9,10 and 11 following tumor injection.

25

Twelve (12) days later, the livers were removed and processed for the histological study. Firstly, they were fixed in a solution of zinc (0.5 g calcium

acetate, 5 g zinc acetate, 5 g zinc chloride and 1000 ml tris buffer, pH 7.4) for 24 hours. Once fixed, they were dehydrated in alcohols of increasing concentrations, and paraffin block were included. Afterward, a minimum of nine (9) cuts 10 μm in thickness were made per liver, leaving a space of 300 μm between every 3 cuts and a 1 mm space between successive groups of 3 cuts. Once the sections had been obtained, they were processed and stained with hematoxylin-eosine. On the one hand, the number, mean diameter, area and position coordinates of each metastasis were quantified by means of an integrated image analysis system (Olympus Microimage 4.0 capture kit) connected to an Olympus BX51TF microscope. With obtained data, metastatic parameters (that is to say, the number of focal points per 100 mm^3 of hepatic tissue) and metastatic volume (that is to say, the volume of liver occupied by metastatic tissue) were calculated as described by Vidal-Vanaclocha et al. [cf. Vidal-Vanaclocha, F., Amézaga, C., Asumendi, A., Kaplanski, G. & Dinarello, C.A. "Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases", *Cancer Research*, 1994, vol. 54, pp. 2667-2672]. On the other hand, more cuts were made in the same blocks, and a double marking with CD31 and desmine was performed to calculate the number and length of the angiogenic vessels within the metastases and also to study metastases according to their angiogenic pattern in portal-type expansive metastases (the angiogenic vessels surround the metastases) or sinusoidal type invasive metastases (containing an internal network of angiogenic capillaries). Another parameter that was quantified is the cavitated metastasis percentage. Lastly, immunohistochemical detection of Ki67 antigen was performed to assess the number of tumor cells which proliferated per unit of tumor surface.

Test of hepatic retention of luciferase-transfected MB16 cells .(MB16-Luc)
(see Table 1). B16M Cells were stably transfected by lipofection as described previously (Rubio N, Martinez-Villacampa M, Blanco J. Traffic to lymph nodes of PC-3 prostate tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker. *Lab Invest* 1998;78:1315-1325), using plasmid pRc/cytomegalovirus-luciferase, a construct containing the *Photinus pyralis* luciferase gene coding sequence under transcriptional control of the cytomegalovirus promoter and the neomycin resistance gene

to the G418 antibiotic (Sigma Chemicals Co.). A total of 300,000 viable B16M-Luc cells were intrasplenically injected into C57BL/6J mice (10 mice per group) which had previously been nasogastrically administered 2 doses of 1 mg/kg/day of compound to be tested. One group of mice received resveratrol, the other group of mice received azaresveratrol. The group of control mice were administered the same solution of the compounds. All mice were killed by cervical dislocation 18 h later and the livers were processed as described previously (Rubio et al, 1998) to measure luciferase activity by chemiluminescence using the standard luciferase assay kit (Promega Co., Madison, WI) as reported (Rubio et al, 1998). Production of light was measured using a luminometer designed to read individual samples tubes (bioorbit, LKB Wallac; Turku, Finland) after the addition of 100 μ l of luciferase assay reagent to 20 μ l of each liver homogenate. Light detector measurements were expressed in relative light units, which were proportional to photon numbers. Linearity and sensitivity of light detection in liver homogenates and influence of hepatic microenvironment on luciferase activity of B16M-Luc were also evaluated as described previously (Rubio et al, 1998).

Table 1

IN VIVO TESTS	CONTROL	+RESVERATROL	+AZARESVERATROL
Hepatic retention of MB16-Luc cells (No. cells $\times 10^6$)	1.80 \pm 0.23	1.95 \pm 0.3	0.98 \pm 0.24
Hepatic focal point density (No. focal points/100mm ²)	60.0 \pm 11	30.0 \pm 11	28.0 \pm 10
No. portal metastases/No. sinusoidal metastasis	30/30 (1)	22.5/7.5 (3)	22.5/5.5 (4.09)
Volume of hepatic metastasis (mm ³)	66.0 \pm 7.5	18.7 \pm 7.5	24.0 \pm 9.0
Length of angiogenic vessels (μ m)	175.0 \pm 10	88.0 \pm 23	88.0 \pm 21
Percentage of focal points w/cavitation (% of total no. of metastatic focal points)	13.5 \pm 5.0	41.5 \pm 11	40.0 \pm 10
Metastatic cell proliferation index (% cells positive to Ki67 antigen)	71.0 \pm 5.0	40.0 \pm 5.0	35.0 \pm 10

Example 17. c).- General formula (ii) compound biological activity results:

In vivo test results:

5 Firstly, a comparative study was made between the effect of the resveratrol and the general formula compound (azaresveratrol) on the intrasinusoidal retention of the tumor cells throughout the first 18 hours and their capacity to develop metastasis on day 12 following their inoculation (see Table 1).

10 Both treatments significantly ($P < 0.05$) reduced the intrahepatic retention of tumor cells 18 hours following their injection. These retention experiments were conducted with MB16 cells transfected with the luciferase gene (MB16-Luc precisely as previously described in the methods employed. In addition thereto, the daily administration of 1 mg/Kg/day of resveratrol and
15 azaresveratrol nasogastrically reduced the mean density of hepatic metastases by 50% and 46%, respectively, which denotes a statistically significant ($P < 0.01$) antimetastatic effect in comparison to the control animals. The immunohistochemical staining for CD31 and desmine revealed that the treatments affected to a greater degree the metastases
20 with a sinusoidal-type angiogenic pattern, also known as invasive metastases, whilst they had almost no effect on the number of metastases having a portal-type angiogenic pattern, or expansive metastases. On the other hand, the percentage of hepatic volume occupied by metastatic tissue decreased by 40% in the treated animals. Said inhibition in the volume had
25 a reduction in the length of angiogenic vessels, a larger percentage of metastatic foci with internal cavitation and a lower tumor cell proliferation index as determined by immunohistochemistry for Ki67 antigen (see Table 1). These results prove, on one hand, that the general formula compound (azaresveratrol) has an *in vivo* antimetastatic efficiency similar to natural
30 resveratrol and, on the other hand, that the effect is two-way, affecting both the stroma as well as the tumor cells directly.

In vitro test results:

35 In following, a series of *in vitro* tests are conducted for identifying the mechanisms of action of the azaresveratrol on the different stages of the development of the metastases. The results are compared in relation to

those obtained with resveratrol.

5 Table 2 shows that the preincubation of the MB16 cells with 2.5 μ M of resveratrol and azaresveratrol for 30 minutes prior to adding IL-18 significantly ($P < 0.01$) inhibited the increase of both the percentage of adhesion of tumor cells to the HSE and the production of tumoral H2O2 in response to IL-18. Not statistically significant differences were found between the two compounds. Likewise, this inhibitory effect was also observed in adhesion tests of A375 human melanoma cells incubated with 10 μ M H2O2 for 2 hours or with 1 ng/ml IL-18 for 6 hours to immobilized VCAM-1 substrates. Therefore, the azaresveratrol inhibited early processes to the metastatic implantation such as tumoral adhesion to the vascular endothelium.

10 To determine whether the compounds affect mechanisms associated with metastatic development and growth, migration tests are conducted on primary human cultures of hepatic stellate cells (HSC) and hepatic sinusoidal endothelial cells (HSE) in response to soluble factors from MA375 cells (see Table 3). When the HSE and HSC cells were administered 12.5 μ M both of resveratrol and azaresveratrol 30 min prior to the MC-A375, the increase in migration induced by the tumor was abolished. On the other hand, the same treatment abrogated the increase in HSC proliferation in response to the inhibition of the migration of HSE cells and HSCs as well as of the proliferation of the latter of the two explains the antiangiogenic effect of the compounds observed in the *in vivo* experiments.

25 An evaluation was also carried aout to determine the direct effect of the resveratrol and azaresveratrol on the proliferation of B16 and A375 cells in response to soluble factors secreted by HSCs. As shown in Table 4, the treatment with MC-CEH for 48 hours significantly ($P < 0.01$) increased the proliferation of melanoma cells. This increase in the proliferation was prevented by incubating the cells with 2.5 μ M of both resveratrol and azaresveratrol for 30 minutes before adding the MC-CEH's.

Table 2

IN VITRO TESTS	CONTROL	TREATMENT	+ RESVERATROL	+ AZARESVERATROL
Adhesion of MB16 cells treated with IL-18 to HSE cells (% adhered cells)	24.4 ± 4	54 ± 6.0	30 ± 4.0	31 ± 4.0
H ₂ O ₂ production by MB16 cells treated with IL-18	16.0 ± 3	34 ± 3.0	12 ± 1.0	19 ± 2.0
Adhesion of MA375 cells with H ₂ O ₂ to immobilized VCAM-1 (% cells adhered)	21.0 ± 4	41.3 ± 4.2	6.5 ± 0.5	4.5 ± 0.3
Adhesion of MA375 cells treated with IL-18 to immobilized VCAM-1 (% cells adhered)	21.0 ± 4	31.5 ± 3.2	5.5 ± 0.4	5.0 ± 0.3

Example 17. d).- Biological activity results for general formula (III) and (IV) compounds:

5

In vitro test results:

10 Firstly, the effect of the formula (III) compounds on the prometastatic behavior of the tumor cells was studied. In Fig. 2, it was observed that the preincubation of the MB16 cells with the JE1:2, JE2:1 and JE2:2 compounds significantly ($P < 0.01$) inhibits the increase in the percentage of H₂O₂-treated melanoma cell adhesion to the immobilized VCAM-1. The JE2:2 compound is the one showing the greatest inhibitory effect.

15 In the proliferation tests (see Fig. 3), the treatment with 10 ng/ml of the proinflammatory cytokine IL-18, produced a statistically significant ($P < 0.01$) increase in the number of MB16 cells in relation to the cells receiving basal medium. Once again, the pretreatment with JE1:2, JE2:1 and JE2:2 compounds reduced said increase and confirms that the JE2:2 compound
20 as being the most highly effective. All of the determinations are made in triplicate.

25 Later, for the purpose of proving the antioxidant effect of the JE2:2 compound, tests were conducted on H₂O₂ production by MB16 cells in response to recombinant IL-18. See Fig. 4, where the treatment with the JE2:2 compound inhibited the production of H₂O₂ of cells in basal conditions and completely abrogated ($P < 0.01$) the increase in H₂O₂ caused by IL-18.

Because H₂O₂ released by the hepatic sinusoidal endothelium (HSE) facilitated the adhesion of melanoma cells and the development of hepatic metastasis, an additional evaluation was accomplished on the effect of the compounds on tumor-activated HSE cells. As shown in Fig. 5, pretreatment of HSE with the JE2:2 compound at a concentration of 2.5 μM inhibited endothelial production of H₂O₂ and significantly (P<0.01) reduced the increase in adhesion of MB16 cells to the HSE activated by soluble factors of the melanoma (see Fig. 6).

10

It was also checked whether any of the intermediary compounds in the chemical synthesis of the JE2:2 compound also has the capacity to inhibit tumor cell adhesion. Two of the compounds, called JEM2:2-01 and JEM2:1-02 are tested. On the other hand, the preincubation of the MB16 cells with 2.5 μM of the JEM2:2-01 compound completely abrogated the increase in tumor cell adhesion to immobilized VCAM-1 induced by H₂O₂ (see Fig. 7). On the other hand, tumor adhesion to HSE cells treated with MC-MB16 in the presence of both of these two compounds was determined. In Fig. 8A, both compounds, JEM2:2-01 and JEM2:1-02, significantly (P<0,01) reduced the proadhesive response induced in the HSE cells by soluble factors from MB16. A greater inhibition was observed with JEM2:2-01 compound, indicating that it is the only one which completely abrogated the inflammatory response of the endothelium, given that it inhibits the endothelial production of TNF-alpha induced by the MB-MB16 (see Fig. 8B).

20

Next, a screening procedure was carried out among the general formula (IV) compounds based on the *in vitro* tests on H₂O₂-treated MB16 cell adhesion to immobilized VCAM-1 or to monolayers from primary cultured HSE cells preincubated or not with MC-MB16. All of the compounds tested (YEF02, YEF03, YEF07, YEF05B, YEF07B and YEF05H) significantly (P<0.01) inhibited the increase in adhesion of MB16 cells to immobilized VCAM-1 substrate induced by treatment with H₂O₂ (see Fig. 9) and also significantly (P<0.01) reduced the proadhesive response of HSE to soluble factors from MB16 cells (see Fig. 10).

30

35

Given that the antimetastatic effect of many natural antioxidants, such as resveratrol, is attributed to the capacity thereof to inhibit cyclooxygenases, an EIA was then conducted to determine PGE2 concentration secreted by HSE cells incubated in the presence or absence of the synthetic compounds and treated or not with VEGF. The compounds tested are those showing a greater inhibitory effect in the previous experiments, in other words, the JE2:2, YEF07 and YEF05B compounds (see Fig. 11). All of the compounds significantly inhibited the increase in the endothelial secretion of PGE2 produced after incubating the HSE cells with 10 ng/ml VEGF for 4 hours. The inhibitory effect was also observed in some cases with the cells cultured under basal conditions. With the concentrations tested, a dose-response was solely observed with the JE2:2 compound in the presence of the VEGF. Therefore, the synthesized compounds are somehow regulating the activity of the cyclooxygenases.

In vivo test results:

In following, as study was made as to the *in vivo* antimetastatic capacity of the JE2:2 compound by selecting it as the leading compound of the families studies both for its inhibitory activity of all of the parameters studied *in vitro* as well as for its being highly water-soluble. To this end, the MB16 cells were intrasplenically injected in C57BL/6J mice (3×10^5 viable cells per animal resuspended in endotoxin-free sterile saline solution), 12 days after which the capacity thereof of development metastasis was determined.


One group of mice (n=7) were administered an intraperitoneal injection of JE2:2 (2.5 mg/kg) 1 hour prior to tumor cell injection, and the same dose was repeated on days 2,3,4,8,9,10 and 11 in following thereto. The group of control mice (n=7) was administered PBS.

As is shown in Fig. 11, the treatment with JE2:2 reduced the mean density of hepatic metastasis by 87% and the volume occupied by metastatic tissue by 90%, which meant a statistically significant ($P < 0,01$) antimetastatic effect in comparison to the control mice administered PBS.

CLAIMS

1.- A nitrogenated trans-stilbene analog compound of the following general formula (I):

5



10 or any of the salts thereof, wherein:

(X) is selected between the imine or pyrrol groups, wherein the pyrrol group can be bonded to the aromatic ring (A) by one or two of the pyrrol ring carbons;


15

$R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$ and R^{10} may be the same or different and represent a hydrogen atom or a group selected between alkoxy or hydroxyl, wherein at least three of these substituents are either alkoxy and/or hydroxyl;

20

R^5 is absent when the pyrrol ring is bonded to the ring (A) by two carbon atoms.

25 2.- A compound according to Claim 1, wherein (X) is a imine group of the following formula (II):




or any of the salts thereof, wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 y R^{10} are of the same meaning as described in Claim 1.

5 3. A compound according to Claim 1, wherein (X) is a pyrrol group which can be bonded to the aromatic ring (A) by one or two of the pyrrol ring carbons.

4. A compound according to Claim 3, of formula (III):



10

or any of the salts thereof, wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 and R^{10} are of the same meaning as described in Claim 1;

15

(Y) represents a hydrogen atom or a group selected from nitro, amino, linear or branched alcoxycarbonyl, amide or an organic or inorganic quaternary ammonium salt;


20

(W) represents a hydrogen atom or a group selected from carboxyl, alcoxycarbonyl or aminocarbonyl;

(Z) represents a hydrogen atom or a group selected from a linear or branched alkyl, benzyl, carboxyl, arylmethyl, heteroarylmethyl, O-alkyl(aryl)carbonyl or N-alkyl(aryl)semicarbazide.

25

5.- A compound according to Claim 3, of formula (IV):



5 or any of the salts thereof, wherein:
 R^1 , R^2 , R^3 , R^4 , R^6 , R^7 , R^8 , R^9 y R^{10} are of the same meaning as described in
 Claim 1;

(Z) is of the same meaning as stated in Claim 4; and

10

(U) represents a hydrogen atom or a linear or branched alkyl group

6.- A compound according to any of Claims 1-5, wherein the alcoxyl group
 is a methoxy.

15

7.- Compound according to Claim 2, wherein the derivative is 5-((E)-(4-
 Hydroxyphenylimine) methyl)benzene-1,3-diol.

8.- Compound according to any of Claims 1, 3 and 4, wherein (Z) is a
 20 hydrogen atom; (W) is a group selected between $-\text{COOCH}_3$ and $-\text{COOH}$;
 (Y) is a hydrogen atom or a group selected between $-\text{NH}_2$ and $-\text{NO}_2$; R^1 , R^5 ,
 R^6 and R^{10} are a hydrogen atom; and R^2 , R^3 , R^4 , R^7 , R^8 and R^9 are the
 same or different and represent a hydrogen atom or a group selected
 between on $-\text{OCH}_3$ and $-\text{OH}$.

25

9.- Compound according to Claim 8, wherein (Z) and (Y) are hydrogen
 atoms.

10- Compound according to Claim 8, selected from the following group: 3,5-
 30 bis(3,5-Dihydroxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 3,5-bis(3,5-
 Dimethoxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 5-(3,5-Dihydroxyphenyl)-

3-(4-hydroxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 3-(4-methoxyphenyl)-
5-(dimethoxyphenyl)-1*H*-pyrrol-2-carboxylic acid; 5-(3,5-dimethoxyphenyl)-
3-(4-methoxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 5-(3,5-
5 dimethoxyphenyl)-3-(4-methoxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 5-
(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1*H*-pyrrol-2-carboxylate;
4-amino-3,5-bis(3,5-dimethoxyphenyl)-1*H*-pyrrol-2-methyl carboxylate; 5-
(3,5-dimethoxyphenyl)-3-(4-methoxyphenyl)-4-nitro-1*H*-pyrrol-2-methyl
carboxylate; 3,5-bis (3,5-dimethoxyphenyl)-4-nitro-1*H*-pyrrol-2methyl
carboxylate; 3,5-bis(3,5-dimethoxyphenyl)-1*H*-pyrrol-2-carboxylic acid; and
10 3-(3,5-Dihydroxyphenyl)-5-(4-hydroxyphenyl)-1*H*-pyrrol-2-methyl
carboxylate.

11.- Compound according to any of Claims 1, 3 and 5, wherein (Z) is a
hydrogen atom or a $-\text{COOC}(\text{CH}_3)_3$ group; (U) is a hydrogen atom; and R^1 ,
15 R^2 , R^3 , R^4 , R^6 , R^7 , R^8 , R^9 are R^{10} the same of different and represent a
hydrogen atom or a group selected between $-\text{OCH}_3$ and $-\text{OH}$.

12.- Compound according to Claim 11 hereinabove, selected from among
the following group: 2-(2,5-dihydroxyphenyl)-1*H*-indole-4,6-diol; 4,6-
20 Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-indole; 4,6-Dimethoxy-2-(2,5-
dimethoxyphenyl)-1*H*-indole-1-tert-butyl carboxylate; 4,6-Dimethoxy-2-(2,5-
dimethoxyphenyl)-1*H*-indole; y 4,6-Dimethoxy-2-(3,5-dimethoxyphenyl)-1*H*-
indole-1-tert-butylcarboxylate.

25 13.- Method for obtaining the compound according to Claim 2, comprising
the following steps:

i) reacting an aromatic aldehyde with a aniline in the presence or
absence of an organic solvent;

ii) purification by crystallization in a suitable solvent.

30

14.- Method according to Claim 13, wherein a drying agent is added to the
reaction mixture.

15.- Method for obtaining the compound according to Claim 4, comprising the following steps:

i) reacting an imine, a nitroalkene, a metallic salt and a tertiary organic base;

5 ii) in the presence of microwave radiation or in the presence of an organic solvent, at a temperature ranging from -25°C to +25°C;

iii) a mixture of 2-alkoxycarbonyl pyrrolidines is obtained which is dissolved in cyclic ether with an oxidizing agent at a temperature ranging from 60°C to 250°C;

10 iv) a mixture of 2-alkoxycarbonyl-NH-pyrrol and 2-alkoxycarbonyl-4-nitro-NH-pyrrol is obtained, which are separated by fractioned crystallization or chromatography;

v) starting from the compounds obtained in iv) hereinabove, a general formula (III) compound is achieved by means of chemical transformations.

16.- Method for obtaining the compound according to Claim 5, comprising the following steps:

i) reacting a amine, an alpha-halocetone and a tertiary amine;

20 ii). In the presence of microwave radiation at a temperature ranging from 90°C to 180°C, with a radiation power ranging from 25 W to 200 W, for a time period ranging from 5 minutes to 30 minutes, at a pressure of 50-200 psi.

iii) the compound 2-aril-1H-indoles is obtained;

25 iv) Starting form the compound obtained in iii) hereinabove, a general formula (VI) compound is obtained by means of chemical transformations.

17.- Method according to Claim 16, wherein the temperature at point (ii) ranges from 130°C to 170°C, the radiation power is 80W-120 W, in a time of 7-15 minutes.

18.- Use of the compounds according to any of Claims 1-12 as antioxidant or anti- inflammatory agent.

- 19.- Use according to Claim 18 for the treatment or chemoprevention of any mammalian disease contributed by undesirable immune, inflammatory, angiogenic or proliferative responses.
- 5 20.- Use according to Claim 19 for the treatment or chemoprevention of anyone of the following mammalian diseases: cancer, fibrosclerosis, acute or chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury, neurodegeneration, or organ transplantation diseases.
- 10 21.- Use according to Claim 20 for the treatment or chemoprevention of carcinogenesis or cancer progression.
- 22.- Use according to Claim 21 for the treatment or chemoprevention of hepatic metastasis.
- 15 23.- Use of the compounds according to any of Claims 1-12 for the preparation of a pharmaceutically-acceptable composition.
- 24.- Use of the compounds according to Claim 23 for the preparation of a composition pharmaceutically-acceptable for the treatment or chemoprevention of any mammalian disease contributed by undesirable immune, inflammatory, angiogenic or proliferative responses.
- 20 25.- Use of the compounds according to Claim 24 for the preparation of a composition pharmaceutically-acceptable for the treatment or chemoprevention of anyone of the following mammalian diseases: cancer, fibrosclerosis, acute or chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury, neurodegeneration, or organ transplantation diseases.
- 25 26.- .- Use of the compounds according to Claim 25 for the preparation of a composition pharmaceutically-acceptable for the treatment or chemoprevention of carcinogenesis or cancer progression
- 30

27.- Use of the compounds according to Claim 26 for the preparation of a composition pharmaceutically-acceptable for the treatment or chemoprevention of hepatic metastasis.

5 28.-Pharmaceutical composition which includes at least one compound according to any of Claims 1-12, in conjunction with a pharmaceutically-acceptable vehicle.

10 29.- Pharmaceutical composition according to Claim 28 which additionally includes a therapeutically active substance.

30.- Pharmaceutical composition according to Claim 29 wherein the therapeutically active substance is quercetin.

15

20

25

30

35

40




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11

